Showing posts with label Neurological. Show all posts
Showing posts with label Neurological. Show all posts

Thursday, April 10, 2008

Caffeine May Block High Cholesterol Linked to Alzheimer's

(HealthDay News) -- A little caffeine every day could offer some protection from Alzheimer's disease for people with high cholesterol.

Rabbits given the daily caffeine equivalent of one cup of coffee and fed a cholesterol-rich diet for 12 weeks suffered relatively little damage in their blood-brain barrier (BBB), which protects the central nervous system from the rest of the body's circulation, new research found.

The findings were published in the open-access publication Journal of Neuroinflammation.

Previous studies have shown that high levels of cholesterol break down the BBB, exposing the central nervous system to damage from blood-borne contamination. BBB leakage occurs in a variety of neurological disorders such as Alzheimer's disease.

"High levels of cholesterol are a risk factor for Alzheimer's disease, perhaps by compromising the protective nature of the blood-brain barrier. For the first time, we have shown that chronic ingestion of caffeine protects the BBB from cholesterol-induced leakage," Jonathan Geiger, of the University of North Dakota School of Medicine and Health Sciences, said in a prepared statement.

Caffeine appears to offer protection by helping proteins maintain the tight binding of the cells in the BBB, so they stop unwanted molecules from entering the central nervous system.

The findings also confirm previous studies showing that caffeine protects against memory loss in aging and in Alzheimer's disease.

"Caffeine is a safe and readily available drug, and its ability to stabilize the blood-brain barrier means it could have an important part to play in therapies against neurological disorders," Geiger said.

More information
The U.S. National Institute on Aging has more about Alzheimer's medications.

Friday, February 22, 2008

Stem Cells Repair Stroke Damage in Rats

(HealthDay News) -- Human stem cells helped repair stroke-related brain damage in rats, Stanford University researchers report.

The use of neural cells derived from human embryonic stem cells led to improvements in the rats' physical abilities, according to the study, which is published in the Feb. 20 issue of Public Library of Science ONE. The stroke damage induced by the researchers left the rats with a weakened forelimb.

This is the first time that scientists have used human embryonic stem cells to generate neural cells that grow well in the lab, repair stroke damage in rats, and don't consistently form tumors after transplantation, according to the researchers.

While the findings show the potential of using stem cell therapies to treat stroke, the researchers noted this is a small study, and more research is needed to determine if this approach could work in humans.

In the laboratory, the researchers grew embryonic stem cells in a combination of growth hormones that prodded the cells to mature into stable neural stem cells. This was an important step, because immature cells tend to grow uncontrollably into tumors.

The neural stem cells were then transplanted into the brains of 10 rats with stroke-related brain damage. After two months, the transplanted neural stem cells had migrated to the damaged area of the brain and incorporated into the surrounding tissue. None of the transplanted cells formed tumors.

The rats that received the transplants were better able to use their forelimbs than rats that had similarly damaged brain regions but weren't given stem cell transplants.

Each year, about 780,000 people in the United States suffer strokes, according to the American Stroke Association.

More information
The U.S. National Institute of Neurological Disorders and Stroke has more about stroke.

Balancing Your Hormones Without Drugs... You Can Feel Good Again

Balancing Your Hormones Without Drugs... You Can Feel Good Again

$19.95
[ learn more ]

Add to Cart

Hormone imbalance can be reversed! Look and feel better than ever, just take the time to learn about yourself and read the information contained in this just released e-book about reversing hormone imbalance. Are you ready to finally look and feel great? If so... read on... - E-Book Version.(BH)

Friday, January 11, 2008

Dementia Diagnosis Typically Means Death Within Five Years

(HealthDay News) -- People with dementia survive an average of four and a half years following their diagnosis, new British research shows.

However, age, sex and any existing disability can alter life expectancy, according to the report in the Jan. 11 online issue of the British Medical Journal.

Common socioeconomic influences, such as marital status, social class and living in a community or residential home, did not appear to have an influence on longevity, the study found.

Researchers analyzed data on more than 13,000 people aged 65 and older who took part in a population-based study in England and Wales and were regularly assessed for dementia between 1991 and 2005.

During the 14-year study period, 438 of the participants developed dementia and 356 (81 percent) of those people died.

Dementia is known to be associated with increased risk of death, but considerable uncertainty exists about what influences survival. Worldwide, the number of people with dementia is estimated to reach 81 million by 2040.

The study found a nearly seven-year difference in survival between the youngest and oldest dementia patients -- 10.7 years for those aged 65 to 69 and 3.8 years for those aged 90 and older.

The average survival time after dementia diagnosis was 4.6 years for women and 4.1 years for men.

People who were the most disabled at the time of diagnosis lived about three years less than those who were the least disabled.

People with more education had a slightly shorter length of survival than those with less education, but researchers said the difference was not statistically significant.

Understanding factors that affect survival time after a dementia diagnosis may help health-care providers, patients, caregivers and policymakers, the study authors said.

More information
The U.S. National Institute of Neurological Disorders and Stroke has more about dementia.

Tuesday, September 18, 2007

Gene Mutation Linked to Parkinson's Disease

(HealthDay News) -- People who carry a certain gene mutation appear to have a greater risk for getting Parkinson's disease and for getting it at a relatively early age, new research suggests.

The study authors also found that because Ashkenazi Jews -- those with an Eastern European background-- are more likely to carry this gene mutation, this population may run an even higher risk for the disease. An estimated 90 percent of American Jews are of Ashkenazi lineage.

Study lead author Lorraine N. Clark, a researcher at Columbia University, described her team's findings as "unique and different."

"We specifically compared patients who had an early onset Parkinson's before age 50 with patients who had a later onset after age 50, and also with patients with and without Jewish ancestry," she said. "And we showed that mutations are twice as common among early onset Parkinson's and also that they're more frequent among patients with Jewish ancestry."

Clark serves as an assistant professor in the department of clinical pathology with the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, as well as the Center for Human Genetics, both at Columbia University.

The findings are published in the Sept. 18 issue of the journal Neurology.

Parkinson's disease is a brain disorder that affects 1.5 million Americans, according to National Parkinson Foundation estimates. Approximately 60,000 news cases occur each year, striking men and women equally, usually over the age of 65.

The disease is characterized by widespread damage to dopamine-producing nerve cells, impeding their ability to regulate body movement and muscle control. Key signs of the disease include tremors, stiffness, balance problems, and slowness of movement. Patients may also experience difficulty with speech and depression. There is no known cure.

To explore potential genetic underpinnings to the onset of Parkinson's, Clark and her colleagues decided to focus on the GBA gene. Mutations of this gene have already been identified as the cause of Gaucher disease, a rare fat-storage disorder that disrupts spleen and brain function.

Gaucher's and Parkinson's have some links, the study authors noted. In some cases, Gaucher's patients have a family history of Parkinson's, while others actually develop neurological features of Parkinson's. It is also one of the most prevalent genetic illnesses among Ashkenazi Jews.

For the new study, the researchers conducted a sequencing analysis of the GBA gene among 278 Parkinson's patients, 178 of who were of Jewish ancestry dating back to all four grandparents. A similar analysis was done among 179 men and women without Parkinson's.

Clark and her team found that 14 percent of the Parkinson's patients had GBA mutations, compared to just 5 percent of the healthy patients. And, while GBA mutations were found among 22 percent of Parkinson's patients who were diagnosed with their illness before the age of 50, only 10 percent of patients diagnosed after 50 had such abnormalities.

Teasing out information on Jewish patients, the researchers found that while nearly 17 percent of Jewish Parkinson's patients had GBA mutations, the figure was 8 percent among non-Jewish Parkinson's patients.

Clark called the study findings preliminary, and she cautioned that it remains unclear whether a single GBA mutation is a cause of Parkinson's or merely a part of a larger puzzle.

Still, she believes the findings could prove helpful in opening up new avenues of research into the disease.

"This is a gene we hadn't really thought about before," she said. "And it implicates new pathways that might be important in the pathogenesis of Parkinson's disease which could lead to the development of new treatment strategies. I do think, however, that further studies are needed in larger patient populations before we could use this work in diagnostic testing and counseling."

Robin Elliott, executive director of the Parkinson's Disease Foundation in New York City, called the new research "very interesting and very worthwhile, solid work in one of the most fruitful areas of Parkinson's research.

"Genetics and the study of genetics has been one of the most exciting areas of Parkinson's in the last 10 years," he said. "In 1996, we had not a single gene associated with the disease, and now it's up to 12 or 13. So, this is a very important study that pushes the science even further, and gives us the basis for more work."

More information
To learn more, visit the Parkinson's Disease Foundation.

Thursday, August 30, 2007

Saline Reduces Mortality for Brain Injury Patients

(HealthDay News) -- A simple change in the way people with traumatic brain injuries are treated initially might make a big difference in their survival odds, a new Australian study suggests.

The study found that using saline rather than albumin fluid to maintain normal fluid volume levels in people with severe brain injuries resulted in nearly double the survival rate at 24 months after the injury.

"We determined that the 2-year mortality rate was significantly high in those patients who received albumin-based fluids compared to those who received saline, particularly those patients with severe brain injuries who presented with traumatic coma," said the study's lead author, Dr. John Myburgh, director of the division of critical care and trauma at the George Institute for International Health, in Sydney.

"Given the significant difference in mortality that we observed, we recommend that albumin-based fluids be avoided for the acute fluid resuscitation of patients with traumatic brain injury," added Myburgh, who's also a professor of critical care at the University of New South Wales.

Results of the study are published in the Aug. 30 issue of the New England Journal of Medicine.

Traumatic brain injury is caused by a sharp blow to the head that often occurs in falls, motor vehicle crashes or from physical assault, according to the U.S. Centers for Disease Control and Prevention. The CDC estimates that about 1.4 million traumatic brain injuries occur annually in the United States, and about 50,000 of those people die as a result of the injury each year.

Those who survive may have lifelong disabilities.

Some of the most serious damage to the brain occurs at the time of the injury, and soon after, when the brain swells in response to the injury. Because the brain is an enclosed system, if swelling occurs, brain tissue becomes damaged.

Fluid resuscitation is a common part of traumatic brain injury treatment to ensure normal blood circulation in the brain, according to the study. However, there's been some debate as to what type of fluid would most benefit people with traumatic brain injuries -- saline or albumin fluid.

Albumin is the main protein component of human blood.

"Albumin is a very expensive product that has to be purified," explained Dr. Keith Siller, medical director of the Comprehensive Stroke Care Center at New York University Medical Center in New York City. "If they're equally effective, you'd pick the cheaper fluid."

And, in fact, a previous study had compared the two fluids and found no statistically significant difference in the rates of death after 28 days.

But, Myburgh and his colleagues re-analyzed the original data to assess results at 24 months after injury. In the original study, 460 people with traumatic brain injuries were randomly selected to receive either saline or albumin fluid. Slightly more than two-thirds of the participants in each group were classified as having a severe traumatic brain injury.

After two years, the researchers behind the new study found that people with traumatic brain injuries who received albumin had a 63 percent higher risk of dying than those given saline. For those with severe brain injuries, the albumin group had an 88 percent increased risk of death compared to the saline group.

"These are people in very bad shape," said Siller. "If there's anything that can help them have better outcomes, we have to pay attention."

Dr. James Goodrich, director of pediatric neurosurgery at the Children's Hospital at Montefiore in New York City, said, "This is a great study that definitely found a significant difference in the sense of outcomes." But, he added, it just confirms what's already going on in the treatment of people with serious brain injury. "Albumin has pretty much been given up on," he said.

As to why saline might offer some benefit over albumin, Myburgh said the researchers can't explain the difference. "The exact mechanism by which the difference in mortality between saline and albumin remains unclear," he said.

"It's probably one of two things," said Siller. "Either albumin is making the brain swelling worse, or somehow the saline is doing something beneficial that albumin can't."

More information
To learn more about traumatic brain injury, visit the National Institute of Neurological Disorders and Stroke.

Wednesday, November 01, 2006

More Dirty Drug Company Secrets

Newer drugs are not always better or safer. They are promoted more vigorously, and patients and doctors often request them thinking a more recent drug must be an improvement.

But a 2002 study of more than 42,000 patients found that generic diuretics were not only cheaper than newer drugs, but also more effective at lowering blood pressure.

Treating high blood pressure with generic diuretics could save the U.S. health care system as much as $10 billion each year.

New drugs can also be more dangerous. As a result of advice from their staff of specially trained pharmacists, the Kaiser Permanente Health System's Drug Information Services never added the painkiller Vioxx or the MS drug Tysabri to its formulary list of covered prescription drugs. Doctors were allowed to prescribe them only if there was no alternative.

Both Vioxx and Tysabri were eventually pulled from the market; Vioxx because of increased risk of heart attack and stroke, and Tysabri because it could cause a rare neurological disease called progressive multifocal leukoencephalopathy, or PML.

USA Today October 18, 2006

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Friday, October 20, 2006

Marijuana-Like Compound May Slow Alzheimer's

(HealthDay News) -- A new U.S. study finds that marijuana may help slow the progression of Alzheimer's, while a second report suggests the "club drug" Ecstasy could yield insights into Parkinson's disease.

Both findings were presented Wednesday at the annual meeting of the Society for Neuroscience, in Atlanta.

In the first presentation, researchers from Ohio State University in Columbus found that marijuana may contain compounds that can slow memory loss associated with Alzheimer's disease.

In their study involving rats, a team led by psychology professor Gary Wenk searched for ways to reduce Alzheimer's-linked brain inflammation.

Wenk was already familiar with data that found that long-term marijuana users had lower rates of Alzheimer's disease than the general population. His team sought to find a compound that might reduce disease-linked brain inflammation but avoid the drug's psychoactive effects.
"We are using a component of marijuana that stimulates the same centers in the brain that marijuana does," Wenk said. The synthetic compound, which is very similar in composition to marijuana, is called WIN-55212-2 (WIN).

Experiments conducted on young and old rats revealed that WIN is "a very effective anti-inflammatory, it reduces brain inflammation," Wenk said.

What makes this discovery special is that this compound can cross the blood-brain barrier, Wenk explained. The results of a special rat "maze test" suggested that WIN "also reversed the memory impairment in the older rats," he said.

Brain inflammation is characteristic of many diseases other than Alzheimer's, including multiple sclerosis, ALS, AIDS, Huntington's and Parkinson's, Wenk noted. "We are beginning to notice that brain inflammation is always in the background as people get older," he said. "Inflammation doesn't cause the disease, it contributes to the pathology," he said.

WIN is not appropriate for use in humans because it still contains substances that may trigger a "high." However, Wenk hopes that some form of this compound might be used to benefit people with neurological diseases.

"We have the added advantage that millions of doses [of marijuana] have been taken by millions of people over the past centuries," he said. "We already know a lot about its actions in the body and its toxicity, or lack of toxicity. The only problem we have is that it's illegal."

Wenk is not suggesting that Alzheimer's patients start using marijuana. "Patients would have to be so careful not to get too much," he said. "That would only worsen the symptoms of their dementia."
The challenge is to find a dose that has an anti-inflammatory effect but does not make patients high, Wenk said. "It's hopeful," he said, "but it's not a therapy until we find a way to make it work in humans."

One expert believes it may be possible to derive therapeutic benefits from marijuana without inducing other effects that could be harmful to Alzheimer's patients.

"These are still early days for thinking about drugs derived from cannabis," said Dr. Samuel Gandy, director of the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia.
"Still, we know the structure of tetrahydrocannabinol (THC) [the active ingredient in cannabis] in detail, and it is not inconceivable that helpful THC-based drugs could be created chemically that benefit brain function but lack the 'high' that currently stigmatizes the compound," Gandy added.

In the second report, researchers from the University of Cincinnati found that, in rats, MDMA (methylenedioxymethamphetamine) -- more commonly known as the illegal drug Ecstasy -- increases the survival of dopamine-releasing cells in the brain during fetal development.
"The club drug Ecstasy can cause dopamine neurons to grow and prevent them from dying off," explained lead researcher Jack Lipton, a professor of psychiatry.

Dopamine cells are critical to the regulation of voluntary movement. This discovery might lead to better therapies for neurological diseases such as Parkinson's, the researchers said.
Ecstasy, as is, is not beneficial for Parkinson's patients, Lipton cautioned. But a part of MDMA may be.

The trick now is to find the components of MDMA that have this effect on dopamine cells and develop ways to use it to help Parkinson's patients, Lipton said. It could also be used as an adjunct to stem cell transplantation, something that's now being studied in Parkinson's patients.
"It could help transplants take better and have more cells survive," Lipton said.

More information
There's more on Alzheimer's disease at the Alzheimer's Association.

ClickComments

Balancing Your Hormones Without Drugs... You Can Feel Good Again

Balancing Your Hormones Without Drugs... You Can Feel Good Again

$19.95
[ learn more ]

Add to Cart

Hormone imbalance can be reversed! Look and feel better than ever, just take the time to learn about yourself and read the information contained in this just released e-book about reversing hormone imbalance. Are you ready to finally look and feel great? If so... read on... - E-Book Version.(BH)